The story of Viagra and its parent , copyright, presents a complex picture for prospective investors. While the revolutionary drug initially fueled enormous revenues , its patent has lapsed , leading to generic versions flooding the market . This reduction in cost presents a substantial obstacle for copyright and any portfolio considering a signifi